A Simplified Method for Generating Kidney Organoids from Human Pluripotent Stem Cells
April 13th, 2021
6.4K views
Here we describe a protocol to generate kidney organoids from human pluripotent stem cells (hPSCs). This protocol generates kidney organoids within two weeks. The resulting kidney organoids can be cultured in large-scale spinner flasks or multi-well magnetic stir plates for parallel drug-testing approaches.
Overview
This article presents a robust and cost-effective 3D protocol for generating large quantities of uniform kidney organoids from human pluripotent stem cells (hPSCs). The method emphasizes reproducibility, scalability, and improved organoid health, making it suitable for disease modeling, therapeutic development, and drug testing.
Key Study Components
Area of Science
- Stem cell biology
- Kidney development and disease modeling
- Organoid technology
Background
- Kidney organoids derived from hPSCs are valuable for studying renal disease, injury, and development.
- Uniformity and reproducibility are critical for experimental consistency and therapeutic applications.
- Existing protocols can be complex, expensive, or yield variable results.
- Improved protocols are needed to generate large numbers of healthy, uniform organoids efficiently.
Purpose of Study
- To refine and simplify kidney organoid generation from hPSCs.
- To enhance organoid health and uniformity.
- To provide a scalable, reproducible, and cost-effective protocol for widespread laboratory use.
Methods Used
- Culture of hPSCs to 60% confluency, with careful maintenance below 80% confluency.
- Formation of embryoid bodies in E5-ILP medium with supplements and GSK3 inhibitor (CHIR99021) for 3 days.
- Use of ultra-low attachment plates and orbital shaker or static culture to prevent clumping and ensure uniform size.
- Size selection of embryoid bodies (200–500 μm) using cell strainers.
- Transfer to spinner flasks or magnetic stir plates for further differentiation in Stage II medium.
- Regular medium changes and careful handling to maintain organoid quality.
- Immunofluorescence analysis to confirm nephron segment and endothelial cell marker expression.
Main Results
- The protocol yields large numbers of uniform kidney organoids with reduced variability.
- Organoids display nephron segments, including renal tubules and podocyte clusters, as confirmed by marker expression.
- Protocol modifications support expansion of endothelial cells within organoids.
- Proper Dispase treatment and washing are critical to prevent cell death and clumping.
- The method is simple, inexpensive, and adaptable to most cell culture laboratories.
Conclusions
- This protocol enables efficient, reproducible generation of kidney organoids from hPSCs.
- It facilitates studies of renal development, congenital kidney diseases, and injury pathways.
- The approach supports therapeutic and drug discovery applications in vitro.
Frequently Asked Questions
What are the key advantages of this kidney organoid protocol?
The protocol is simple, cost-effective, and yields large numbers of uniform organoids, making it suitable for high-throughput studies and reproducible assays.
Why is uniformity in organoid size important?
Uniform organoid size reduces variability between samples, improving experimental consistency and reliability of results.
How are embryoid bodies formed and selected for size?
Embryoid bodies are formed in supplemented medium and agitated to prevent clumping. They are then filtered using 200–500 μm cell strainers to select the optimal size range for organoid development.
What markers confirm the presence of nephron segments in organoids?
Immunofluorescence shows renal tubules expressing HNF1β and Lotus tetragonolobus lectin, and podocyte clusters expressing MafB and nephrin.
Can this protocol be performed in standard cell culture laboratories?
Yes, the method is designed for use in any laboratory equipped for cell culture, without the need for specialized equipment.
What are critical steps for maintaining high-quality hPSC cultures?
Cells should be kept below 80% confluency, split regularly, and thoroughly washed after Dispase treatment to prevent cell death and clumping.
What applications are enabled by these kidney organoids?
The organoids can be used to study renal development, congenital kidney diseases, injury pathways, and for testing potential therapeutic interventions in vitro.
Executive Industry Relevance
Uniform kidney organoids derived from human pluripotent stem cells (hPSCs) address a critical need for scalable, reproducible renal models in early drug discovery and disease research. This protocol enables high-throughput generation of consistent organoids, supporting predictive confidence in preclinical assays and translational studies. The approach streamlines workflow integration for renal target validation and compound screening across biopharma portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of renal developmental pathways and disease mechanisms in a controlled 3D system.
- Supports functional validation of kidney-specific targets using human-derived tissue models.
- Facilitates mechanistic de-risking by providing reproducible, disease-relevant organoid platforms.
Screening & Assay Development
- Delivers large quantities of uniform organoids for standardized, quantitative compound testing.
- Reduces assay variability through size selection and agitation, improving reproducibility.
- Prepares validated biological systems for downstream screening and phenotypic analysis.
Translational & Preclinical Research
- Aligns with disease-relevant human kidney biology for translational biomarker studies.
- Enables continuity from early discovery through preclinical validation of renal therapeutics.
- Supports in vitro modeling of congenital kidney diseases and injury pathways.
Pipeline & Workflow Integration
This protocol fits from early discovery through lead identification and preclinical research, providing a reusable platform for renal biology studies and compound evaluation.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification in human kidney tissue context.
- Screening: Offers reproducible, quantitative outputs for reliable compound assessment.
- Analytics: Enables measurement of nephron segment markers and organoid uniformity for comparative studies.
- Translational Research: Bridges discovery and preclinical phases with disease-relevant organoid models.
- Enterprise Reuse: Adaptable to various renal research and screening initiatives across R&D teams.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in renal studies.
- Operational Value: Standardizes organoid production for scalable, reproducible workflows.
- Strategic Value: Improves go/no-go decision quality and capital efficiency in renal drug discovery.
- Portfolio Impact: Enables risk-adjusted prioritization of renal targets and therapeutic candidates.
Implementation Considerations
- Requires expertise in hPSC culture and differentiation protocols.
- Needs access to cell culture infrastructure, orbital shakers, and size selection strainers.
- Demands rigorous cross-team standardization for reproducibility.
- Adaptable to different hPSC lines and renal disease models with protocol optimization.
- Dependent on precise Dispase treatment and washing to prevent cell death and clumping.
Biopharma FAQs
Why does null hypothesis testing matter for kidney organoid target validation?
Null hypothesis testing using uniform kidney organoids enables objective assessment of renal target function and intervention effects. This reduces bias and increases confidence in early-stage target validation decisions for renal drug discovery.
How does independent variable isolation fit the embryoid body size selection workflow?
Isolating embryoid bodies by size (200–500 μm) ensures that only organoids with comparable developmental potential are analyzed, allowing clear attribution of observed effects to experimental variables rather than size-related confounders.
What do quantitative nephron marker measurements enable in organoid assays?
Quantitative measurement of nephron segment markers, such as HNF1β and nephrin, enables benchmarking of organoid differentiation quality and supports comparative analysis across experimental conditions and compound treatments.
Why are replication requirements critical for cross-functional kidney organoid studies?
Replication ensures that organoid-based findings are robust and transferable across teams, supporting collaborative assay development and reliable data for portfolio decision-making in renal research programs.
What statistical analysis capabilities are required before implementing organoid-based screening?
Robust statistical analysis of organoid size distribution, marker expression, and assay reproducibility is essential to validate assay performance and ensure reliable interpretation of screening results in biopharma workflows.
Chapters in this video
0:04
Introduction
0:59
Setting up the Kidney Organoid Assay and Feeding by Half-Medium Change
2:49
Transfer of Embryoid Bodies to Stage II Medium
4:49
Transfer to Spinner Flask and Feeding
5:37
Setting up a 6-Well Magnetic Stir Plate
6:14
Results: Immunofluorescence of the Kidney Organoids
6:51
Conclusion
